
KEEP UP WITH THE LATEST IN INDUSTRY NEWS!
From news about new medicines, pharmacy business insights, and the pharmaceutical industry in general—this is your source!
DrugTopics articles
- New Test Could Help Identify Patients That Would Benefit From Blood Thinners February 15, 2025Currently, blood-thinning medications are only prescribed to patients who have already had a heart attack or stroke, as the drugs can cause serious bleeding.
- FDA Approves Merilog as Biosimilar to Insulin Aspart for Diabetes February 14, 2025The drug is the first rapid-acting insulin biosimilar product approved for use by the FDA, marking a significant milestone in diabetes treatment.
- Neuroactive Steroid Levels May Indicate Risk of Postpartum Depression February 14, 2025Identifying women who are at risk for postpartum depression sooner can lead to quicker and possibly preventative treatment.
- Learning Sessions, Shared Decision Making Could Help Increase Vaccinations Among Older Adults February 14, 2025Among providers who took part in a recent study, 57% reported increased vaccination rates after implementing a quality improvement initiative.
- E. Coli Vaccine Candidate Fails to Demonstrate Efficacy in Phase 3 Trial February 14, 2025Investigators note there were no safety signals related to the vaccine candidate, and participants who developed E. coli disease received treatment and care.
- Focus on What Matters: Sustaining Your Pharmacy in 2025 February 13, 2025What are some key strategies for keeping your pharmacy thriving in 2025?
- FDA Grants Fast Track Designation to Cannabis Withdrawal Syndrome Therapy February 13, 2025A dose response is observed with the highest dose of the drug and mitigating withdrawal symptoms for patients with cannabis use disorder.
- Keeping Focus on Bottom Line Amid Industrywide Changes in Pharmacy February 13, 2025Pharmacy industry experts gathered for a webinar detailing the upcoming trends expected to take shape in 2025.
- 2025 ACIP Immunization Schedules February 13, 2025More detailed information can be found on the CDC’s website at www.cdc.gov/vaccines.
- Tirzepatide Facilitates Greater Weight Loss, Strongest Antihypertensive Effects February 13, 2025For weight loss and antihypertensive effects on systolic and diastolic blood pressure, semaglutide also had increased effects.
Pharmacy Times articles
- Targeting Nectin-4 and HER2 in Urothelial Cancer: The Evolving Role of ADCs February 15, 2025Enfortumab vedotin, trastuzumab deruxtecan, and disitamab vedotin were highlighted at the 2025 ASCO Genitourinary Cancers Symposium.
- Etranacogene Dezaparvovec-drlb Delivers Sustained, Increased Bleed Protection Compared With Prophylaxis in Hemophilia B February 15, 2025A one-time infusion of etranacogene dezaparvovec-drlb led to sustained bleeding control and a reduction in factor IX prophylaxis in patients with hemophilia B.
- Enhancing Outcomes With Immunotherapy Agents for Patients With Non-Muscle Invasive Bladder Cancer February 14, 2025Panelists at the 2025 ASCO Genitourinary Cancers Symposium discussed challenges and new approaches to treatment.
- RSV in Older Adults: Risks, Prevention, and the Pharmacist's Role February 14, 2025RSV poses a significant threat to high-risk adults, but effective vaccines offer strong protection, highlighting the need for increased vaccination rates and education.
- Rapid-Acting Insulin Biosimilar Receives FDA Approval for Diabetes February 14, 2025Insulin-aspart-szjj (Merilog) is the first rapid-acting insulin biosimilar product approved by the FDA.
- FDA Approves Vimseltinib for the Treatment of Adults With Symptomatic TGCT February 14, 2025The indication is for symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity.
- FDA Grants OPN-6602 Orphan Drug Destination for Treatment of Patients With Relapsed, Refractory Multiple Myeloma February 14, 2025OPN-6602 is an oral EP300/CBP bromodomain inhibitor that yielded 100% tumor regression as a combination therapy in mouse models.
- First-Line Enfortumab Vedotin, Pembrolizumab Superior to Chemotherapy in Patients With Urothelial Carcinoma February 14, 2025The combination of the antibody-drug conjugate and PD-1/L1 inhibitor yielded an improved progression-free survival in locally advanced or metastatic urothelial carcinoma.
- Potential Drug for Mitigation of Cannabis Withdrawal Symptoms Receives FDA Fast Track Designation February 14, 2025PP-01 could become a first-in-class treatment for patients with cannabis use disorder.
- Darolutamide Improved Survival in Phase 3 Trials for Patients With Metastatic Hormone-Sensitive Prostate Cancer February 14, 2025The data were presented at the 2025 ASCO Genitourinary Cancers Symposium in San Francisco, California.

Helping You Navigate the Returns Process!
Pedigree Statement
Flash Returns, LLC has strict standard operating procedures and a pharmaceutical services agreement (PSA) with it’s clients…
Flash Returns, LLC has strict standard operating procedures and a pharmaceutical services agreement (PSA) with its clients. This is to ensure that the reverse distribution portion of the supply chain that we service keeps its functionality and integrity for our customers and the public.
Several pedigree and distribution level issues have been raised in the industry. Discounted, indigent-pricing, short dated, bulk purchase, secondary distribution, or DSCSA non-compliant sales could affect the credit available for a product based on a manufacturers determination. We ask that you do not return these products for credit as they are not eligible in most cases. Flash Returns LLC may choose to dispose of these on the pharmacies behalf at no charge if the cost is low relative to the return. Most customers purchasing products from reputable wholesalers will not encounter these issues, however all pharmacies are asked to acknowledge our policy on pedigree and legitimacy of product here and by signing the PSA before a return is initiated.
Some manufacturers may require proof the price paid for a product and what wholesaler distributed the product. Issues causing triggering this could be: bulk or large quantities of single items or lots, or products purchased speculatively. In some cases we may request invoices from the customer to ensure Flash Returns or manufacturer policy is being met. If none are available or if the information isn’t accepted by the manufacturer it could cause the return to be non-returnable.
Flash Returns, LLC cannot guarantee or be liable for the value or credit for products that were purchased outside of manufacturer accepted distribution channels. This could include products: purchased from a wholesaler that is not an approved vendor, products not purchased directly from a particular manufacturer, purchased on a speculative basis, diverted or counterfeit products, foreign products, and any product purchased on a non-returnable basis, including short-dated product purchased at discounted pricing.
At any time, Flash Returns, LLC or a manufacturer may require invoices or pedigree information demonstrating proof of purchase. If product has been shipped by Flash Returns, LLC or the Customer to a manufacturer or their agent, Flash Returns, LLC cannot guarantee or facilitate the return of product to the Customer. Manufacturers reverse the right to destroy product they deem not credit worthy or suspect. Manufacturers agreeing to return product to customers will do so at the customers expense. Flash Returns, LLC shall not be responsible for reimbursing a Customer for such product.
If Customer is unable to have product returned within 21 days, product is subject to be destroyed without any payment or credit issued to Customer. In any dispute, failure by Customer to provide invoices for a product or pedigree if requested shall release Flash Returns, LLC from any and all liability of products involved in dispute including the full value of the product. More information on drug pedigrees is available on the FDA website at:
Pedigree Statement
P: 833.553.5274
E: SignUp@FlashReturns.com